When it comes to psychedelics, today’s article notes that “While this industry is still in its early stages, the promising pInovio Pharmaceuticals went from being one of the early front runners in the COVID-19 vaccine race to stalling out in the U.S. when the phase 3 portion of its trial was put on hold. But with the company having turned to other regions to complete its program – and early data showing its vaccine candidate may have potential against a range of SARS-CoV-2 variants – this COVID vaccine opportunity may still be in play. For more, CLICK HERE.
COVID-19 Vaccine Stocks: Is Inovio Still In Play?
